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Abstract
Background: Cognitive deficits in schizophrenia are associated with psychosocial deficits that are primarily responsible 
for the poor long-term outcome of this disease. Auditory sensory gating P50 deficits are correlated with 
neuropsychological deficits in attention, one of the principal cognitive disturbances in schizophrenia. Our studies 
suggest that the α7 nicotinic acetylcholine receptor (α7 nAChR) agonist tropisetron might be a potential therapeutic 
drug for cognitive deficits in schizophrenia. Therefore, it is of particular interest to investigate the effects of tropisetron 
on the cognitive deficits in patients with schizophrenia.
Methods: A randomised, placebo-controlled trial of tropisetron in patients with schizophrenia was performed. A total 
of 40 patients with chronic schizophrenia who had taken risperidone (2 to 6 mg/day) were enrolled. Subjects were 
randomly assigned to a fixed titration of tropisetron (n = 20, 10 mg/day) or placebo (n = 20) in an 8-week double-blind 
trial. Auditory sensory gating P50 deficits and Quality of Life Scale (QLS), Cambridge Neuropsychological Test 
Automated Battery (CANTAB), and Positive and Negative Syndrome Scale (PANSS) scores were measured.
Results: In all, 33 patients completed the trial. Tropisetron was well tolerated. Administration of tropisetron, but not 
placebo, significantly improved auditory sensory gating P50 deficits in non-smoking patients with schizophrenia. The 
score on the rapid visual information processing (sustained visual attention) task of CANTAB was significantly improved 
by tropisetron treatment. Total and subscale scores of PANSS were not changed by this trial. QLS scores in the all 
patients, but not non-smoking patients, were significantly improved by tropisetron trial.
Conclusions: This first randomised, double-blind, placebo-controlled trial supports the safety and efficacy of 
adjunctive tropisetron for treatment of cognitive deficits in schizophrenia.
Background
Cognitive deficits in schizophrenia are frequently severe
and strongly correlated with decreased functional out-
come and quality of life (QOL) [1-5]. Atypical antipsy-
chotics have been shown to provide an improvement in
several domains of cognitive function, especially working
memory, executive function, and attention [2,6]. How-
ever, many patients, even if they are medicated with atyp-
ical antipsychotics, fail to recover from cognitive deficits,
resulting in a failure of their reintegration into society.
Several lines of evidence suggest that the α7 subtype of
the nicotinic acetylcholine receptors (α7 nAChRs) plays
an important role in the mechanism of auditory P50 gat-
ing deficits of schizophrenia, and that α7 nAChR agonists
are potential therapeutic drugs for the deficient inhibi-
tory processing of the P50 auditory evoked potential that
contributes to the cognitive deficits in schizophrenia [7-
17]. Tropisetron (Nabovan), a potent serotonin-3 (5-
hydroxytryptamine; 5-HT3) receptor antagonist, is widely
used in the treatment of patients with chemotherapy-
induced or postoperative nausea and vomiting [18]. It has
also been reported that tropisetron is a partial agonist at
α7 nAChRs with a high affinity (Ki = 6.9 nM for α7
nAChRs; Ki = 5.3 nM for 5-HT3 receptors) [19]. We pre-
viously reported that tropisetron normalises deficient
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auditory gating in DBA/2 mice and that this effect of tro-
pisetron was blocked by coadministration of the selective
α7 nAChR antagonist methyllycaconitine (MLA) [20].
Furthermore, we reported that tropisetron or the selec-
tive α7 nAChR agonist SSR180711, but not the selective
5-HT3 receptor antagonist ondansetron, could ameliorate
phencyclidine (PCP)-induced cognitive deficits in mice,
and that the effects of tropisetron or SSR180711 were
blocked by coadministration of MLA [21,22]. In addition,
we reported that a single oral administration of tropise-
tron (10 mg) could improve deficits in auditory P50 sup-
pression in Japanese schizophrenic patients [23]. The
neuropharmacological and neurobiological effects of tro-
pisetron demonstrated by our group suggest the need for
future studies to assess the effects of tropisetron on cog-
nitive dysfunction in schizophrenia, because P50 deficits
have been previously associated with attentional deficits
in schizophrenia [24]. These attentional deficits are in
turn associated with psychosocial deficits that are pri-
marily responsible the poor long-term outcome of
schizophrenia [1].
This randomised, double-blind, placebo-controlled
study was undertaken to examine whether adjunctive tro-
pisetron could improve cognitive deficits and other clini-
cal variables in patients with schizophrenia. A dose of 10
mg tropisetron was chosen since this dose has been
proven effective in deficits in auditory P50 suppression of
schizophrenia [23]. Risperidone was used as an antipsy-
chotic drug because risperidone does not exhibit signifi-
cant α7 nAChR agonism or 5-HT3 receptor antagonism.
Methods
Participants
The subjects were 40 patients (19 males and 21 females;
age: 35.1 ± 7.63 years (mean ± SD); age range: 21 to 48
years) with schizophrenia meeting the Diagnostic and
Statistical Manual of Mental Disorders, fourth edition
(text revision) (DSM-IV TR) criteria [25] who were out-
patients of Chiba University Hospital, Chiba, Japan (Table
1). As required by the selection criteria, they were clini-
cally stable outpatients with no medical or neurological
illness, or alcohol or other substance dependence. To be
eligible for the trial, all patients had to have been taking
the atypical antipsychotic drug risperidone (2 to 6 mg/
day) for at least 8 weeks, and the dose of this antipsy-
chotic was not changed during the trial. Concomitant
psychiatric medications were permissible (antidepres-
sants, mood stabilisers, anticholinergics, and others)
(Table 2), provided that patients were receiving stable
doses of all of these medications in the 4 weeks preceding
the trial and throughout the entire duration of the study.
In all, 10 patients in the placebo group and 11 patients in
the tropisetron group had taken anticholinergics (biper-
iden or trihexyphenidyl hydrochloride) during the trial.
The difference between the two groups in mean dosage of
anticholinergics was not statistically significant (unpaired
Student t test; P = 0.51). Furthermore, 8 patients in the
placebo group and 12 participants in the tropisetron
group had taken benzodiazepines during the trial. How-
ever, five patients in the placebo group and three patients
in the tropisetron group had taken benzodiazepines dur-
ing the day. Moreover, one patient had taken lithium, and
another patient had taken milnacipran and trazodone in
the placebo group. One patient had taken valproic acid,
and another patient had taken carbamazepine in the tro-
pisetron group. None of the patients had taken tricyclic
antidepressants. None of the patients (except dropouts)
altered his or her medications during the trial. For polyp-
harmacy, four patients in the placebo group and six
patients in the tropisetron group had taken two or more
kinds of drugs within anticholinergics, benzodiazepine
during the day, antidepressants, or mood stabilisers. Any
change in psychiatric medications at any point during the
study rendered a patient ineligible to continue participa-
tion.
Ethics
The trial was approved by the Institutional Review Board
of Chiba University Hospital (Chiba, Japan), and regis-
tered on the Clinical Trials Registry of the University hos-
pital Medical Information Network (UMIN, Tokyo,
Japan). All subjects provided written informed consent
for their participation in the study after the procedure
had been fully explained to them.
Study design
This double-blind, placebo-controlled trial used a ran-
domisation procedure established by UMIN (UMIN
000003084). A total of 20 subjects received 10 mg/day
tropisetron (Nabovan; Novartis Pharma KK, Tokyo,
Japan), and 20 subjects received a matching placebo cap-
sule. Medications were dispensed in blister packs by the
Department of Pharmacy of Chiba University Hospital.
Clinical variables and cognition
The Positive and Negative Syndrome Scale (PANSS) was
used to quantify the severity of psychotic symptoms [26].
Drug-induced extrapyramidal symptoms were assessed
using the Drug-Induced Extrapyramidal Symptoms Scale
(DIEPSS) [27]. Patients were closely monitored for any
adverse events or clinical deterioration. Quality of Life
Scale (QLS) [28] scores were also measured. PANSS,
DIEPSS and QLS scores were measured twice (at baseline
and 8 weeks).
Cognitive function in patients with schizophrenia was
measured by the Cambridge Neuropsychological Test
Automated Battery (CANTAB), which consists of a series
of interrelated computerised non-verbal tests of memory,
attention, and executive function [29-31]. The CANTABShiina et al. Annals of General Psychiatry 2010, 9:27
http://www.annals-general-psychiatry.com/content/9/1/27
Page 3 of 10
tests used in this study were the pattern recognition
memory (PRM: recognition memory for patterns), spatial
recognition memory (SRM: recognition memory for spa-
tial locations), delayed matching to sample (DMS: simul-
taneous and delayed perceptual matching), span length of
spatial span (SSP: working memory capacity), spatial
working memory (SWM: working visuospatial memory
and strategy use), stocking of Cambridge (SOC: spatial
planning and motor control), intra-extra dimensional set
shifting (IED: rule acquisition and attentional set shift-
ing), and rapid visual information processing (RVP; sus-
tained visual attention) [31] tests. In this study,
measurement by CANTAB was performed at baseline
and 8 weeks.
Auditory sensory gating P50
S u b j e c t s  w e r e  s e a t e d  i n  a  c o m f o r t a b l e  r e c l i n e r  a n d
instructed to relax with their eyes open and to focus on a
fixation point. The testing took place in a quiet, lighted
room. The subject was monitored visually and by electro-
encephalogram (EEG) for signs of sleep or slow wave
activity, which prompted the experimenter to speak
briefly with the subject. The 120 pairs of auditory clicks
were presented at a rate of 1 pair every 10 s, with a 500-
Table 1: Characteristics of subjects
Placebo group Tropisetron group P value
Sex (M/F) 10/10 9/11 NSa
Age 35.15 ± 8.54 34.96 ± 6.82 NSb
Subtype Disorganised 1 Disorganised 0 NSa
Catatonia 1 Catatonia 0
Paranoid 13 Paranoid 11
Undifferentiated 2 Undifferentiated 3
Residual 3 Residual 6
Duration of illness 9.79 ± 6.43 12 ± 8.67 NSb
Dose of risperidone 3.8 ± 1.58 4.03 ± 1.59 NSb
No. smoking 5 (25%) 6 (30%) NSa
Full IQ 87.00 ± 16.80 87.68 ± 18.86 NSb
PANSS score Positive: 11.8 ± 3.12 Positive: 11.85 ± 3.22 NSb
Negative: 18.45 ± 6.66 Negative: 18.95 ± 5.23
General: 34.3 ± 7.53 General: 33.75 ± 8.69
Total: 64.55 ± 15.17 Total: 64.55 ± 15.65
QLS total score 77.05 ± 15.8 72.2 ± 13.95 NSb
Rate of completion 17 (85%) 16 (80%) NSa
Reason for dropout Physical illness: 1 Non-adherence: 2
Worsening of illness: 1 Unknown: 1
Adverse effects: 1 
(extrapyramidal signs)
Adverse effect: 1 (chest pain)
Data show the mean ± SD.
aχ2 test; bStudent t test.
NS = not significant; PANSS = Positive and Negative Syndrome Scale; QLS = Quality of Life Scale.
Table 2: Other medications used by patients
Drugs Placebo group (N = 20) Tropisetron group (N = 20)
Anticholinergics N = 10, (mean 2.2 mg/day) N = 11, (mean 1.9 mg/day)
Benzodiazepines N = 8, (with 5 during the day) N = 12, (with 3 during the day)
Other medications Lithium (N = 1), milnacipran and trazodone (N = 1) Valproic acid (N = 1), carbamazepine (N = 1)Shiina et al. Annals of General Psychiatry 2010, 9:27
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ms interclick interval. The stimuli were 1 ms square
waves amplified to 70 dB SPL. Recordings were per-
formed with gold disc electrodes at Fz, Cz, and Pz with a
forehead ground and linked earlobe reference. Data from
the Cz site are presented, since recordings at Cz best dis-
criminate schizophrenia patients from normal subjects
[32]. Eye movements and blinks were monitored by elec-
tro-oculographic (EOG) recording. The resistance of all
electrodes was less than 10 kohm. EEG activity was
recorded by an MEB2208 8-channel system (Nihon Koh-
den, Tokyo, Japan) with filters at 0.5 and 100 Hz. Data
were acquired at a 500 Hz digitisation rate, and individual
trials were stored to disk for analysis. Individual trials
were rejected if the EEG or EOG voltage was greater than
±70 μV, which is generally indicative of excessive muscle
activity, eye movements, or other artefacts. The condi-
tioning P50 wave was identified by a rater blind to the
subject identity and the treatment conditions as the most
positive peak between 40 and 90 ms after the condition-
ing stimulus. The test P50 wave was identified as the pos-
itive peak after the test stimulus that was closest in
latency to the conditioning P50. The amplitude was
defined as the difference between the positive peak and
the preceding negative trough for both waves. The P50 T/
C ratio was calculated by dividing the test P50 amplitude
by the conditioning P50 amplitude. Auditory sensory gat-
ing P50 was measured twice in all patients (at baseline
and 8 weeks). Due to EEG noise, we could not measure
the P50 in three patients of the placebo group.
Statistical analysis
The data were expressed as the mean ± SD. Data analysis
was performed using PASW Statistics 18.0 (formerly
SPSS statistics; SPSS, Tokyo, Japan). The differences
between groups were evaluated by χ2 test and Student t
test. The data on P50 and QLS in each group were
assessed by paired Student t test. Values of P < 0.05 were
considered to indicate statistical significance in these
analyses. First, the data on the eight domains of CANTAB
were assessed by repeated two-way analysis of variance
( A N O V A ) .  N e x t ,  t h e  d a t a  o f  C A N T A B  i n  e a c h  g r o u p
were assessed by paired Student t test since there was no
significant effect. We used a Bonferroni correction for
multiple comparisons of CANTAB data.
Trial registration
University hospital Medical Information Network
(UMIN) Clinical Trials registry No.: UMIN 000003084
http://www.umin.ac.jp.
Results
Participants
Table 1 shows the characteristics of all participants.
There were no differences on their distribution in sex,
age, diagnosis subtype, duration of illness, dosage of ris-
peridone, full IQ, severity of symptoms measured with
PANSS, or QLS total score (Table 1). In all, 33 partici-
pants completed the trial. Four patients in the tropisetron
group dropped out due to non-adherence (n = 2) and
adverse effects (chest pain n = 1, unknown n = 1); and
three patients in the placebo group dropped out due to
physical illness (influenza n = 1), worsening of illness (n =
1), and adverse effects (extrapyramidal side effects n = 1)
(Table 1).
Adverse events
There were no significant effects of drug treatment on
vital signs, ECG, or the results of haematology measure-
ments or serum chemistry tests. One patient in the tro-
pisetron group complained of moderate constipation and
needed to take a laxative. One female patient in the tro-
pisetron group complained of mild chest pain, although
no changes were observed in her ECG (Table 1). After
conferring with the investigator she decided to discon-
tinue the trial. Shortly after discontinuation her symp-
toms vanished without any medical intervention or
worsening of her mental or physical status. None of the
patients showed any remarkable change in their DIEPSS
severity score throughout the trial, and no other adverse
events were observed. Tropisetron was thus well toler-
ated in this trial.
Auditory sensory gating P50 deficits
Administration of tropisetron (n = 16, 10 mg/day for 8
weeks; t = 3.24, degrees of freedom (df) = 15, P = 0.006),
but not placebo (n = 14, t = 0.570, df = 13, P = 0.578), sig-
nificantly improved auditory sensory gating P50 deficits
in patients with schizophrenia (Additional file 1). Next we
analysed the data for non-smokers, since it is well known
that smoking can affect the P50 suppression ratio and
cognition in schizophrenia [33-35]. Administration of
tropisetron (n = 12, 10 mg/day for 8 weeks; t = 2.70, df =
11, P = 0.021), but not placebo (n = 10, t = 1.66, df = 9, P =
0.132), significantly improved auditory sensory gating
P50 deficits in non-smoking patients with schizophrenia
(Figure 1). Subsequently, we analysed the data of non-
smoking patients with schizophrenia.
Cognitive deficits
Repeated two-way ANOVA showed that performance on
the eight domains of the CANTAB did not differ between
tropisetron group and placebo group. Therefore we per-
formed a secondary analysis using a paired Student t test
in each group of non-smoking patients. Some subtests of
CANTAB were significantly improved after the treat-
ment. In the non-smoking placebo group (n = 12), the
scores of correct rate in all trials of DMS (t = -3.94, df =
11, P = 0.002), SSP (t = -2.60, df = 11, P = 0.025), and aShiina et al. Annals of General Psychiatry 2010, 9:27
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prime of RVP (t = -2.77, df = 11, P  = 0.018) were
improved after placebo treatment, but SSP and RVP were
not significant after a Bonferroni correction. However,
DMS was still significant after a Bonferroni correction,
suggesting that a practice effect was operative. Further-
more, the scores for RVP were significantly improved
after treatment with tropisetron (t = -5.78, df = 11, P <
0.001); which was still significant after a Bonferroni cor-
rection (Figure 2). Other subtests of CANTAB were not
changed by this trial. In addition, we did not observe any
significant correlation between P50 changes and RVP
changes in the non-smoking patients with schizophrenia.
Psychotic symptoms and QLS
Total and subscale scores (positive symptoms, negative
symptoms, or general psychopathological symptoms) of
PANSS were not altered by treatment with tropisetron or
placebo (Additional file 2). Furthermore, administration
of tropisetron significantly (t = -2.42, df = 15, P = 0.029)
increased QLS total scores in total patients (n = 16) with
schizophrenia, whereas administration of placebo did not
change QLS total scores (t = -0.72, df = 13, P = 0.487)
(Additional file 3). However, administration of tropise-
tron did not alter QLS total scores in non-smoking
patients (n = 12). In addition, we did not observe any sig-
nificant correlation between P50 changes and QLS score
changes in the total or non-smoking patients with schizo-
phrenia.
Effects of tropisetron on smoking patients
Moreover, we did not observe any effect of tropisetron on
the P50 ratio, psychotic symptoms, QLS, or cognitive
functions in the smoking patients (tropisetron group n =
4; placebo group n = 5), although the sample number in
each group was too small to reach any definitive conclu-
sions in regard to these parameters. In addition, tropise-
tron did not affect smoking status (for example, the
number of cigarettes) in the smoking patients (n = 4).
Discussion
The major findings of this double-blind, placebo-con-
trolled study are that administration of tropisetron, but
not placebo, significantly improved auditory sensory gat-
ing P50 deficits in patients with schizophrenia, and that
tropisetron had a significant impact on the sustained
visual attention measured with the RVP subtest of CAN-
TAB in non-smoking patients. Previously, we reported
that the effect of a single administration of tropisetron
(10 mg) on P50 deficits in patients with schizophrenia
was significant only for the non-smokers [23], indicating
that smoking status can affect P50 deficits in schizophre-
nia. In the present study, we also found that administra-
tion of tropisetron (10 mg/day for 8 weeks), but not
placebo, significantly improved P50 deficits in non-smok-
ing patients with schizophrenia, suggesting that chronic
as well as acute administration of tropisetron (10 mg) can
improve P50 deficits in non-smoking patients with
Figure 1 Effect of tropisetron on auditory sensory gating P50 deficits in non-smoking patients with schizophrenia. The ratio of test P50 am-
plitude to conditioning amplitude was measured at baseline and 8 weeks after placebo or tropisetron treatment. Tropisetron (t = 2.70, degrees of 
freedom (df) = 11, P = 0.021), but not placebo (t = 1.66, df = 9, P = 0.132), significantly decreased the P50 ratio in non-smoking patients with schizo-
phrenia. Data are from the placebo group (n = 10) and the tropisetron group (n = 12).Shiina et al. Annals of General Psychiatry 2010, 9:27
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schizophrenia. Interestingly, we found that sustained
visual attention as measured with the RVP subtest of
CANTAB in non-smoking patients was significantly
improved by tropisetron treatment, but not by placebo
treatment. It has been reported that the α7 nAChR ago-
nist 3-(2,4-dimethoxybenzylidene) anabaseine (DMXB-
A) had effects on auditory P50 deficits, attention/vigi-
lance and working memory Measurement and Treatment
Research to Improve Cognition in Schizophrenia (MAT-
RICS) [36,37] domains in stable and non-smoking
patients with schizophrenia [13,14]. Auditory sensory
P50 deficits have also been shown to be associated with
attentional deficits in schizophrenia [24]. Unexpectedly,
we did not observe any significant correlation between
P50 changes and RVP subtest changes in the non-smok-
ing patients because of the small sample size. A further
study using a large sample size will be necessary. Taken
together, it is likely that the improvement of P50 deficits
by tropisetron is involved in the beneficial effects of this
drug on attention. Furthermore, the results of this trial
suggest that stimulation at α7 nAChRs by α7 nAChR ago-
nists can lead to improvement in auditory P50 deficits
and aspects of cognitive performance such as attention.
Several studies strongly suggest that cognitive deficits
have a major impact on QOL in patients with schizophre-
nia [1,4,38,39]. A recent review of longitudinal studies
demonstrated that cognition deficits are associated with
functional outcomes in schizophrenia, and that cognitive
assessment predicts later functional outcomes in
patients, suggesting a rationale for psychopharmacologi-
cal interventions for cognitive deficits [4]. It is thus signif-
icant that, in the present study, an 8-week treatment with
tropisetron could improve the QOL in total patients with
schizophrenia although this is not significant in the non-
smoking patients. In addition, we did not observe any sig-
nificant correlation between P50 changes and QLS score
change in the non-smoking patients because of small
sample size. A further study using a large sample size will
be necessary. Freedman et al. [14] reported that treat-
ment with DMXB-A significantly improved two sub-
scales (for example, alogia and anhedonia) of the Scale for
the Assessment of Negative Symptoms (SANS), but not
the total score of the Brief Psychiatric Rating Scale
(BPRS). The effects of DMXB-A on negative symptoms
are also noteworthy, as these negative symptoms are gen-
erally resistant to antipsychotic drugs. However, in this
trial, we did not observe any effect of tropisetron on the
positive symptoms or negative symptoms scores of
PANSS. Further detailed studies regarding the effects of
tropisetron on psychotic symptoms such as negative
symptoms will therefore be necessary.
Tropisetron is also a potent antagonist at 5-HT3 recep-
tors. At present, it is unclear whether improvement of
P50 deficits by tropisetron is mediated via direct agonist
effects on α7 nAChRs or via direct antagonist effects on
5-HT3 receptors. Previously, we reported that tropise-
Figure 2 Rapid visual information processing (RVP) scores on Cambridge Neuropsychological Test Automated Battery (CANTAB) subtests 
for non-smoking patients with schizophrenia during treatment placebo and tropisetron. There were significantly different scores for RVP (t = -
5.78, degrees of freedom (df) = 11, P < 0.001) in the tropisetron group, but not the placebo group. Data are from the placebo group (n = 12) and the 
tropisetron group (n = 12).Shiina et al. Annals of General Psychiatry 2010, 9:27
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tron, but not the selective 5-HT3  receptor antagonist
ondansetron, attenuated PCP-induced cognitive deficits
in mice, and that this effect of tropisetron was blocked by
coadministration of the selective α7 nAChR antagonist
MLA [21]. These results suggest that activation of α7 nic-
otinic receptors by tropisetron is likely to play a role in
the mechanism of action of tropisetron [17,21]. In con-
trast, the selective 5-HT3 receptor antagonist ondanse-
tron was reported to improve deficient auditory gating in
DBA/2 mice [40]. In addition, ondansetron was shown to
be effective in auditory P50 deficits, negative symptoms
and cognitive symptoms in patients with schizophrenia
[41-44]. These results suggest that 5-HT3 receptor antag-
onism may contribute to the action of tropisetron. There-
fore, a clinical/feasibility study comparing tropisetron
versus ondansetron with or without placebo will help to
determine whether the addition of the α7 nAChR partial
agonism of tropisetron has enhanced effects versus sim-
ply adding a 5-HT3 receptor antagonist. In contrast, it
seems that DMXB-A addition to an atypical antipsy-
chotic or versus placebo has the advantage of specificity
of action. Nonetheless, in order to confirm the role of α7
nAChRs in the treatment of schizophrenia, a randomised
double-blind, placebo-controlled study of the selective α7
nAChR agonists in patients with schizophrenia would be
necessary.
There were no adverse side effects associated with the
tropisetron trial. Tropisetron, which is already approved
for human use outside the USA, is widely used in the
treatment of patients with chemotherapy-induced or
postoperative nausea and vomiting [18]. Thus, it was not
surprising that tropisetron (10 mg) was well tolerated in
this trial. Freedman et al. [ 1 4 ]  r e p o r t e d  t h a t  n a u s e a
occurred in 45% of a group of patients receiving a high
dose of the α7 nAChR agonist DMXB-A, and this was
suggested to be due to the known effects of nicotinic ago-
nists on gastrointestinal mobility. Considering the high
incidence of nausea among patients treated with α7
nAChR agonists (for example, DMXB-A), it is likely that
α7 nAChR agonists (for example, tropisetron) with 5-HT3
r ec e p t o r  a n ta g o n is m  wi l l  be  s u i t a b l e  t h e r a pe u t i c  d ru gs
for schizophrenia, since 5-HT3 receptor antagonists are
therapeutic drugs for nausea [45].
It has been reported that varenicline, a partial agonist at
α4β2 nAChRs as well as a full agonist at α7 nAChR ago-
nists, was not effective in the auditory P50 deficits in
patients with schizophrenia [46]. The precise reasons
underlying the lack of varenicline on P50 deficits is cur-
rently unknown. One possibility is that the receptor
desensitisation may occur by the time measurement
because varenicline is a full agonist at the α7 nAChRs. A
further detailed study using a selective partial agonist and
a selective full agonist will be necessary. Another possibil-
ity is that there was incomplete absorption of a single
dose of varenicline, leading to insufficient levels of the
drug in the brain [46]. Furthermore, Freedman [47]
reported the case of a patient with schizophrenia who
received varenicline and experienced an activated psy-
chotic relapse. The US Food and Drug Administration
(FDA) and the Institute for Safe Medication Practices
stated that serious neuropsychiatric symptoms including
changes in behaviour, agitation, depressed mood, suicidal
ideation and attempted and completed suicide have
occurred in patients with taking varenicline [48]. There-
f o r e ,  c l ose  m o n i t o ri n g  o f  pa t i e n ts  p r e s cri bed  t h is  d ru g
will be warranted. In contrast, tropisetron and DMXB-A
have not been reported to induce psychosis in patients
with schizophrenia (this study, and [14]). Therefore, it is
likely that tropisetron and DMXB-A have lower risk of
inducing psychosis than varenicline although the reasons
underlying this difference are currently unknown.
Inhibitory interneurons with α7 nAChRs are possible
candidates for medication to ameliorate the habituation
of auditory responses in the hippocampus, because acti-
vation of the interneurons via α7 nAChRs would increase
the inhibitory synaptic input to pyramidal neurons and
thereby diminish the responsiveness of these pyramidal
neurons to sensory stimulation [49]. This parallels a study
of postmortem human tissue that documented a
decreased expression of hippocampal α7 nAChRs in
schizophrenic patients [49]. Furthermore, it has been
reported that [125I]α-bungarotoxin binding to α7 nAChRs
is reduced in the thalamic reticular nucleus of schizo-
phrenic subjects [50], and that α7 nAChR protein levels
are reduced in the frontal cortex in patients with schizo-
phrenia [51]. Thus, it seems that schizophrenic patients
have fewer α7 nAChRs in the hippocampus, a condition
which may lead to failure of cholinergic activation of
inhibitory interneurons, clinically manifested as
decreased gating of the response to sensory stimulation
[17]. Therefore, it is of great interest to study whether the
density of α7 nAChRs is altered in the intact brain of
patients with schizophrenia. A positron emission tomog-
raphy (PET) study using the selective α7 nAChR ligand
[11C]CHIBA-1001 [52,53] in the intact brains of patients
with schizophrenia is currently underway.
Finally, several limitations of this study should be men-
tioned. One of the main limitations of this trial was its
small sample size (total n = 40) and the use of only one
dose (10 mg) of tropisetron. The dose (10 mg) of tropise-
tron used in this study was well tolerated and resulted in
significant effects on P50 deficits, and aspects of cogni-
tive performance such as attention. However, it is cur-
rently unclear if other dosing approaches would be more
efficacious. Very recently, using [11C]CHIBA-1001 and
PET, we found that a single oral administration of tropise-
tron (5, 10 or 20 mg), but not ondansetron, could bind toShiina et al. Annals of General Psychiatry 2010, 9:27
http://www.annals-general-psychiatry.com/content/9/1/27
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α7 nAChRs in the intact human brain in a dose-depen-
dent manner (Ishikawa M, Ishii K, Wu J, Toyohara J,
Sakata M, Oda K, Kimura Y, Iyo M, Ishiwata K, Hashim-
oto K. unpublished results). Therefore, a randomised
double-blind, placebo-controlled study of higher doses
(for example, 20 mg) of tropisetron in patients with
schizophrenia using a larger sample will be needed. In
addition, the duration of treatment in this trial (8 weeks)
was fairly short. A double-blind, placebo-controlled study
with a longer duration (for example, 48 weeks) of tropise-
tron treatment would also be of use. Another limitation
was the possible presence of practice effects for CANTAB
[31], which may have been responsible for the improve-
ment of cognitive performance in the placebo group of
this study. In this study, sustained visual attention mea-
sured with the RVP subtest was significantly improved by
tropisetron, but not by placebo, in non-smokers, suggest-
ing that the effects of tropisetron on RVP might not be
due to practice effects. Furthermore, Freedman et al. [14]
also observed practice effects in a study using the MAT-
RICS Consensus Cognitive Battery to investigate the effi-
cacy of DMXB-A. Therefore, further detailed studies to
validate the use of other cognitive batteries in patients
taking tropisetron, such as MATRICS, Brief Assessment
of Cognition in Schizophrenia (BACS) [54], and the Cog-
State Schizophrenia Battery [55], would be of interest.
In conclusion, the results of the present feasibility study
investigating adjunctive tropisetron as a treatment strat-
egy for cognitive deficits in schizophrenia are promising.
Similar to ondansetron and DMXB-A, tropisetron was
well tolerated in this trial, and was associated with no
untoward effects. If these initial pilot findings are con-
firmed in larger randomised controlled trials, tropisetron
will be a potential therapeutic drug for the treatment of
cognitive deficits and QOL in patients with schizophre-
nia.
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